BUZZ-Eton Pharma rises after US FDA accepts application for hormone disorder drug ** Shares of drugmaker Eton Pharmaceuticals ETON.O rise 3.5% to $14.90 premarket
** Co says the US FDA has accepted its application for potential approval of its drug candidate ET-600
** If approved, ET-600 is expected to be the only oral liquid option on the market for central diabetes insipidius, ETON says
** Central diabetes insipidius is a condition where the body doesn't produce enough vasopressin, a hormone that regulates water balance by signaling kidneys to conserve water
** The FDA will give its decision on ET-600 on or before February 26, 2026
** Up to last close, stock had risen 8% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.